• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Clearside Biomedical

Bausch + Lomb, Clearside Biomedical launch Xipere in U.S.

March 28, 2022 By Sean Whooley

Bausch_Health_ Clearside Biomedical

Bausch Health’s (NYSE:BHC) Bausch + Lomb and Clearside Biomedical (Nasdaq:CLSD) launched their Xipere product in the U.S. today. Clearside Biomedical designed the Xipere triamcinolone acetonide suprachoroidal injectable suspension therapy with a proposed indication for treating macular edema associated with uveitis, a form of eye inflammation. Xipere works with Clearside’s proprietary SCS Microinjector to deliver the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: Bausch Health, bausch&lomb, Clearside Biomedical

FDA accepts resubmitted NDA for Xipere from Clearside Biomedical, Bausch Health

June 2, 2021 By Sean Whooley

Bausch_Health_ Clearside Biomedical

Bausch Health (NYSE:BHC) and Clearside Biomedical (NSDQ:CLSD) announced today that the FDA accepted their resubmitted new drug application for Xipere. Clearside Biomedical designed the investigational Xipere triamcinolone acetonide suprachoroidal injectable suspension therapy with a proposed indication for treating macular edema associated with uveitis. Xipere works with Clearside’s proprietary SCS Microinjector to access the back of […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals Tagged With: Bausch Health, Clearside Biomedical, FDA

Regenxbio pulls trigger on option to license Clearside Biomedical’s SCS Microinjector

October 31, 2019 By Sean Whooley

Clearside Biomedical logo - updated

Clearside Biomedical (NSDQ:CLSD) said yesterday that Regenxbio (NSDQ:RGNX) exercised its option to license Clearside’s in-office SCS Microinjector for delivering adeno-associated virus (AAV)-based therapeutics in treating wet age-related macular degeneration, diabetic retinopathy and other conditions. The two companies inked the option and licensing deal that they said at the time could be worth more than $130 million on […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic Tagged With: Clearside Biomedical, Regenxbio

Clearside Biomedical inks $76m licensing deal with Bausch for Xipere

October 23, 2019 By Sean Whooley

Clearside Biomedical logo - updated

Clearside Biomedical (NSDQ:CLSD) said yesterday that it entered into a license agreement with Bausch Health Ireland (NYSE:BHC) worth up to $76 million for the Xipere device for the treatment of macular edema associated with uveitis. The agreement grants Bausch an exclusive license to develop, manufacture, distribute, promote, market and commercialize the suprachoroidal injection device. Bausch agreed to […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals Tagged With: Bausch Health, Clearside Biomedical

Clearside Biomedical confirms timeline for Xipere

October 21, 2019 By Sean Whooley

Clearside Biomedical logo - updated

Clearside Biomedical (NSDQ:CLSD) last week said that the FDA found no efficacy issues with its Xipere drug-delivery technology and will not ask for further clinical efficacy studies. The Xipere device is a suprachoroidal injection designed for the treatment of macular edema associated with uveitis. In October 2018, Clearside touted data from a Phase III pivotal trial, which reported […]

Filed Under: Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals Tagged With: Clearside Biomedical, FDA

Clearside Biomedical, Regenxbio ink sales deal for gene therapy microinjector

September 5, 2019 By Sean Whooley

Clearside Biomedical logo - updated

Clearside Biomedical (NSDQ:CLSD) has agreed to grant Regenxbio (NSDQ:RGNX) the option to an exclusive worldwide license to sell Clearside’s SCS gene therapy microinjector. The option and licensing deal is potentially worth more than $130 million, the companies said. The SCS microinjector is designed to deliver adeno-associated virus (AAV) gene therapies to treat wet age-related macular […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic, Wall Street Beat Tagged With: Clearside Biomedical, Regenxbio

FDA wants more on new manufacturing process from Clearside Biomedical

August 22, 2019 By Sean Whooley

Clearside Biomedical logo - updated

Clearside Biomedical (NSDQ:CLSD) said today that the FDA ordered the company to provide stability data on its new manufacturing process for triamcinolone acetonide suspension, pushing the timeline on the agency’s decision into next year. Alpharetta, Ga.-based Clearside’s Xipere device is a suprachoroidal injection designed for the treatment of macular edema associated with uveitis. Clearside said […]

Filed Under: Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals Tagged With: Clearside Biomedical

Clearside Biomedical licenses microinjector to Aura Biosciences

July 9, 2019 By Brad Perriello

Clearside Biomedical

Clearside Biomedical (NSDQ:CLSD) said today that it licensed its microinjector technology to Aura Biosciences for use with Aura drug candidates in treating ocular cancers. Alpharetta, Ga.-based Clearside’s Suprachoroidal Space Microinjector is designed to deliver therapeutics into the suprachoroidal space between the sclera and choroid of the eye. Aura, based in Cambridge, Mass., is developing viral nanoparticle […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Research & Development Tagged With: Aura Biosciences, Clearside Biomedical

Clearside Biomedical shares down on Q4 miss

March 13, 2019 By Fink Densford

Clearside Biomedical logo - updated

Shares in Clearside Biomedical (NSDQ:CLSD) have fallen slightly today after the biopharmaceutical company posted fourth quarter 2018 earnings that missed expectations on Wall Street. The Alpharetta, Ga.-based company reported research and development costs of approximately $17.5 million with a total net loss of $21.6 million, or 68¢ per share, for the three months ended December 31, […]

Filed Under: Business/Financial News, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Clearside Biomedical

Clearside Biomedical seeks FDA nod for macular edema injection

December 20, 2018 By Sarah Faulkner

Clearside Biomedical logo - updated

Clearside Biomedical (NSDQ:CLSD) said this week that it submitted a new drug application to the FDA for Xipere – a suprachoroidal injection designed for the treatment of macular edema associated with uveitis. The Alpharetta, Ga.-based company noted that if Xipere is approved by the FDA, it would be the first therapy for macular edema associated with […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Clearside Biomedical

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS